Hims & Hers Stock Declines Amid Amazon Competition

Written by Emily J. Thompson, Senior Investment Analyst

Source: Fool

Updated: 19 hours ago

0mins

HIMS-4.5%

AMZN+0.92%

NVO-0.99%

Should l Buy HIMS?

Source: Fool

Stock Fluctuation: Hims & Hers Health closed at $29.76, down 4.03%, primarily impacted by Amazon's launch of a competing GLP-1 weight-loss program, although it gained 39.33% over the past week.
Surge in Trading Volume: Trading volume reached 56.7 million shares, about 50% above the three-month average of 37.8 million shares, indicating increased market interest in the stock.
Intensified Market Competition: Amazon's same-day delivery service poses a threat to Hims & Hers' core business, especially following the resolution of a legal dispute with Novo Nordisk over weight-loss drugs, which has dampened market sentiment.
Investor Watch: Investors will closely monitor the potential impact of Amazon's new offering on Hims & Hers' revenue and subscriber numbers, particularly as the company is set to announce its Q1 results on May 11.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on HIMS

Wall Street analysts forecast HIMS stock price to rise

12 Analyst Rating

3 Buy

6 Hold

3 Sell

Hold

Current: 29.760

Low

16.50

Averages

32.95

High

60.00

Current: 29.760

Low

16.50

Averages

32.95

High

60.00

BofA

analyst

Neutral

maintain

$25 -> $30

2026-04-22

New

Reason

BofA

analyst

Price Target

$25 -> $30

AI Analysis

2026-04-22

New

maintain

Neutral

Reason

BofA raised the firm's price target on Hims & Hers (HIMS) to $30 from $25 and keeps a Neutral rating on the shares. Amazon's (AMZN) new offering in the GLP-1 market appears well suited for long-term GLP-1 subscribers that may opt to minimize ongoing costs, says the analyst, who anticipates it could further pressure Hims' GLP-1 revenue in 2026 and beyond. The firm cites a raised multiple to reflect peptide optionality and peer multiple expansion, offset by yesterday morning's Amazon news, for its news Hims target.

Citi

Neutral

maintain

$24

2026-04-21

New

Reason

Citi

Price Target

$24

2026-04-21

New

maintain

Neutral

Reason

After Amazon One Medical (AMZN) launched a GLP-1 management program, Citi noted that if a patient is already a One Medical subscriber, they can get a prescription through their One Medical primary care provider. However, if a patient is not a One Medical subscriber, they can access an \"on demand\" provider for as low as $29 per visit to renew a prescription, but the \"big caveat\" is this option is only available for renewals, not new prescriptions, and it seems patients are limited to two renewals per year. While this \"theoretically could be a significant threat\" to platforms that charge membership fees greater than $100 per month ex-medications, such as Hims, the on-demand option is \"not a replacement for these platforms,\" the analyst tells investors. Citi has a Neutral rating and $24 price target on Hims & Hers (HIMS) shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HIMS

Unlock Now

About HIMS

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Trump Extends Ceasefire with Iran Amid Market Volatility

3 hours agoCNBC

Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.

Trump Extends Ceasefire with Iran Amid Market Volatility

4 hours agoNewsfilter

Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.

Amazon's GLP-1 Program Limits Impact Hims

14 hours agostocktwits

Amazon's GLP-1 Program Limits: Citi highlighted that Amazon's $29 telehealth option is restricted to prescription renewals, not new prescriptions, which may reduce the competitive threat to Hims' subscription model, impacting its market position.
Hims Stock Volatility: Hims & Hers Health, Inc. (HIMS) saw its shares drop over 4% to $29.76 in extended trading on Tuesday, although they rebounded by more than 1% after hours, indicating mixed market sentiment regarding its future prospects.
Hims Expanding New Areas: Hims is diversifying into hormone health, with the FDA recently encouraging testosterone therapy exploration for men with low libido, potentially opening new market opportunities while also advancing FDA-approved GLP-1 therapies.
Positive Market Sentiment: Despite competition from Amazon, Hims has been viewed as “extremely bullish” on Stocktwits, with message volumes surging 384% over the past week, reflecting investor confidence in its innovative capabilities.